导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.54% | 1858/4773 |
| 近一周 | -2.69% | 2852/5462 |
| 近一月 | -1.68% | 999/5421 |
| 近一季 | -3.48% | 1416/5209 |
| 近半年 | -7.09% | 3174/4920 |
| 近一年 | 3.36% | 1944/4366 |
| 近两年 | 53.47% | 1383/2954 |
| 近三年 | 36.81% | 808/2253 |
| 成立以来 | 297.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.07% 1374/4961 |
0.27% 3195/5312 |
- - |
- - |
| 2025 | 24.89% 1759/4813 |
2.57% 1326/3635 |
2.81% 1337/4076 |
18.49% 2295/4524 |
-0.05% 2330/4813 |
| 2024 | 10.80% 1371/3463 |
4.30% 460/2808 |
-2.84% 1264/3014 |
10.96% 2571/3129 |
-1.45% 1710/3463 |
| 2023 | 0.23% 418/2656 |
9.19% 422/2280 |
-2.23% 571/2385 |
-2.82% 760/2515 |
-3.38% 675/2655 |
| 2022 | -14.08% 357/2207 |
-6.49% 216/1919 |
0.84% 1523/2016 |
-10.32% 382/2113 |
1.59% 1209/2208 |
| 2021 | 33.38% 52/1822 |
5.81% 104/1255 |
4.01% 936/1330 |
12.15% 101/1466 |
8.07% 165/1822 |
| 2020 | 40.77% 302/1250 |
0.12% 171/1028 |
14.86% 533/1067 |
17.38% 104/1164 |
4.28% 853/1184 |
| 2019 | 27.73% 534/1092 |
28.04% 327/754 |
-6.20% 497/804 |
-0.52% 599/850 |
6.90% 522/918 |
| 2018 | -26.97% 408/834 |
- - |
- - |
- - |
-11.04% 244/691 |
| 2017 | 3.14% 430/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.04% 207/605 |
- - |
- - |
- - |
- - |
| 2015 | 36.28% 54/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银河定投宝 VS. 长安沪深300非周期A(740101) |